Baylor College of Medicine

ASCENT-GYN-01: Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer (H-56008)

Description

Content

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC).

The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).

For more information: https://clinicaltrials.gov/study/NCT06486441

IRB: H-56008

Status:

Active

Created:

Back to topback-to-top